Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: A single-center experience with preemptive therapy

Transplantation Proceedings

Volumn 37, Issue 6, 2005, Pages 2684-2687

  De Santo, L S ^a   Romano, G ^b   Mastroianni, C ^a   Roberta, C ^a   Della Corte, A ^a   Amarelli, C ^b   Maiello, C ^b   Giannolo, B ^b   Marra, C ^b   Ragone, E ^b   Grimaldi, M ^b   Utili, R ^b   Scardone, M ^b   Cotrufo, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b MONALDI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBIOTIC THERAPY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MORBIDITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RELAPSE; SUPERINFECTION; SURGICAL RISK; VIRUS LOAD;

EID: 25144480530     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.06.080     Document Type: Article

References (9)

1. R.H. Rubin Prevention and treatment of cytomegalovirus disease in heart transplant patients J Heart Lung Transplant 19 2000 731
2. S. Kusne, P. Grossi, W. Irish Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients Transplantation 68 1999 1125
3. R. Casillo, M. Grimaldi, E. Ragone Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients Transplant Proc 36 2004 651
4. L.S. De Santo, A. Della Corte, G.P. Romano Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation Transplant Proc 36 2004 631
5. L.E. Gamadia, E.B. Remmerswaal, J.F. Weel Primary immune responses to human cytomegalovirus a critical role for IFN-gamma-producing CD4-T cells in protection against CMV disease Blood 101 2003 2686
6. K. Krogsgaard, S. Boesgaard, J. Aldershvile Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy Scand J Infect Dis 26 1994 239
7. A.O. Zuckermann, M. Grimm, M. Czerny Improved long-term results with thymoglobuline induction therapy after cardiac transplantation; a comparison of two different rabbitantithymocyte globulines Transplantation 69 2000 1890
8. J. Kobashigawa, L. Miller, D. Renlund Mycophenolate Mofetil Investigators A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 66 1998 507
9. J.D. Hosenpud, L.E. Bennett Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization an analysis of the Joint UNOS/ISHLT Thoracic Registry Transplantation 72 2001 1662